Dacomitinib

Drug Profile

Dacomitinib

Alternative Names: PF-00299804; PF-299; PF-299804; PF-804

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Fondazione IRCCS Istituto Nazionale dei Tumori; Pfizer; Seoul National University Hospital; SFJ Pharmaceuticals; University Health Network; University of California, San Diego
  • Class Antineoplastics; Quinazolinones; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Brain metastases; Gastric cancer; Squamous cell cancer
  • Phase I/II Orofacial cancer
  • Phase I Head and neck cancer; Solid tumours
  • Discontinued Glioblastoma

Most Recent Events

  • 02 Jun 2017 Efficacy and adverse events data from a phase II trial in Squamous cell cancer presented at the (53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 14 Jun 2016 University of California at San Diego and Pfizer terminate a phase II trial in Brain metastases in USA (NCT02047747)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top